Introduction
A 25-year-old lady was brought to the Emergency Department of our hospital half an hour after having consumed 10 tablets of aluminium phosphide (ALP) 50%. At the time of presentation, she was nauseated and had several episodes of vomiting. Her heart rate was 120/min, BP was 110/75 mmHg, she was breathing at a rate of 20 min, with oxygen saturations around 98-99% on room air. Initial blood gas analysis revealed signifi cant metabolic acidosis with a pH: 7.33, PaCO2: of 23.3, HCO3: 12.1 and base excess: −13.8. A gastric lavage was given and she was transferred to the intensive care unit where she was put on invasive blood pressure and central venous pressure monitoring. Her initial liver function tests, blood urea nitrogen, creatinine, creatinine kinase, troponin -I and magnesium levels were within the normal range. Four hours after admission, she developed hypotension (systolic pressures less than 90 mmHg and
Case Report
Fatal aluminium phosphide poisoning due to myocardial depression refractory to high dose inotropic support and intra-aortic balloon counterpulsation initiation of CVVHD, her acidosis improved, though she continued to remain tachycardic and hypotensive in spite of increasing doses of adrenaline. An echocardiogram revealed severe impairment of left ventricular function with an ejection fraction of 30% on high level of inotropic support with dobutamine and adrenaline. Her troponin-I level had increased at this point in time to 12.7 ng/ml (normal level: 0.0 to 0.4 ng/ml). In view of her worsening cardiac function in spite of increasing doses of inotropic support, an intraaortic balloon pump was inserted to support LV function. Augmentation was commenced at 1:2 support considering her signifi cant tachycardia. The IABP had no apparent effect on her hemodynamic status even after several hours of support. She continued to be tachycardic, hypotensive with high central venous pressures and persisting metabolic acidosis in spite of ongoing CVVHD. Despite continued supportive measures, she never showed any improvement and died about 48h after admission to the intensive care unit.
Discussion
Aluminium phosphide (ALP) is used as a rodenticide and is a common agent used in suicidal attempts in northern India. Refractory myocardial depression from ALP toxicity is not uncommon and carries a mortality of up to 77%. [1, 2] ALP releases phosphine gas when it comes in to contact with moisture, which is then absorbed rapidly through the gastrointestinal tract, lungs or the skin. Phosphine causes non-competitive inhibition of mitochondrial cytochrome oxidase. [3] This has been suggested to inhibit myocardial cellular metabolism and necrosis of the cardiac tissue resulting in the release of reactive oxygen intermediates. [4] Hypomagnesaemia has been known to cause arrhythmias in ALP poisoning and magnesium supplementation has been suggested as a therapeutic option. [2] However, supplemental magnesium had no discernible effect on our patient. Intraaortic ballon counterpulsation (IABP) has been used successfully as a temporizing measure in toxicity due to other myocardial depressant agents. [5] [6] [7] We tried IABP to try to mechanically support the heart. Even after several hours of optimal augmentation, this had no positive effect on our patient's hemodynamic status. We did consider the option of using cardiopulmonary bypass (CPB) as a support measure, however, the fairly rapid terminal phase of her illness did not permit us to do so.
We present a case of refractory myocardial depression from ALP toxicity. In spite of inotropic support with high doses of dobutamine and adrenaline, our patient went on a rapid downhill course with worsening tachycardia, hypotension, metabolic acidosis and very high troponin-I levels, possibly due to extensive myocardial necrosis. There was no improvement in her hemodynamic status with intraaortic balloon counterpulsation. To our knowledge, there is no other report in literature of IABP use to try to support the myocardium in ALP poisoning. The possible benefi t of CPB would need to be explored in refractory myocardial depression due to ALP.
